Who makes SB-1121(2)?

SB-1121(2) is developed by Nguyen Thi Trieu, MD.

What development phase is SB-1121(2) in?

SB-1121(2) is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

SB-1121(2)

Nguyen Thi Trieu, MD · FDA-approved active Small molecule Quality 5/100

SB-1121(2), marketed by Nguyen Thi Trieu, MD, is a drug with an unknown mechanism of action and a key composition patent expiring in 2028. The primary strength of SB-1121(2) lies in its current market presence, despite the lack of detailed clinical trial results and revenue data. The primary risk is the potential loss of market exclusivity upon patent expiry in 2028, which could lead to increased competition.

At a glance

Generic name	SB-1121(2)
Also known as	Cirrhosis/Hcc/SB-1121
Sponsor	Nguyen Thi Trieu, MD
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Composition for Treating Cirrhosis and Liver Cancer (SB-1121) (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

SB-1121(2) CI brief — competitive landscape report
SB-1121(2) updates RSS · CI watch RSS
Nguyen Thi Trieu, MD portfolio CI